CryoPort Q4 Earnings Beat Expectations Despite EPS Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy CYRX?
Source: seekingalpha
- Earnings Highlights: CryoPort reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.06; however, revenue reached $45.5 million, reflecting a 9.6% year-over-year increase and beating market expectations by $2.58 million, indicating robust growth in the biopharmaceutical logistics sector.
- Annual Revenue Guidance: The company provided a revenue guidance for FY 2026 of $190 million to $194 million, projecting an 8% to 10% year-over-year growth, which reflects a positive outlook on future market demand and may attract more investor interest in its long-term growth potential.
- Market Reaction: Despite the EPS miss, the strong revenue performance could boost investor confidence in the short term, potentially driving the stock price up and improving the company's image in the capital markets.
- Industry Outlook: With the ongoing expansion of the biopharmaceutical industry, CryoPort's growth potential is significant, particularly in cold chain logistics and biological sample transportation, which is expected to further solidify its market position and drive future business development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CYRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CYRX
Wall Street analysts forecast CYRX stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.600
Low
11.00
Averages
11.00
High
11.00
Current: 13.600
Low
11.00
Averages
11.00
High
11.00
About CYRX
Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cryoport Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Cryoport reported Q1 revenue of $47.8 million, a 16% year-over-year increase, with commercial cell and gene therapy revenue rising 26% to $9.1 million, underscoring the company's market leadership and robust demand.
- Innovative Clinical Trial Support: As of March 31, Cryoport supported a record 766 global clinical trials, including 91 in Phase III, reflecting the company's strong influence in the biopharmaceutical sector and the ongoing growth in market demand.
- Optimistic Outlook: The company raised its full-year 2026 revenue guidance to $192 million to $196 million, expecting to achieve positive adjusted EBITDA in the second half of the year, indicating management's confidence in future performance and market potential.
- Product and Service Expansion: Cryoport introduced its new Fusion 800 series and successfully shipped its first cryopreserved clinical trial materials from its Houston and Belgium facilities to clients, marking significant progress in product delivery and market expansion.
See More
CRYOPORT Q1 REVENUE REACHES USD 47.8 MILLION, EXCEEDING IBES ESTIMATE OF USD 44.9 MILLION
- Revenue Comparison: Cryoport reported a revenue of USD 47.8 million for Q1, exceeding the estimated revenue of USD 44.9 million by Ibes.
- Financial Performance: The significant difference between actual revenue and estimates indicates a strong performance by Cryoport in the first quarter.
See More
CryoPort to Announce Q1 Earnings on May 4th
- Earnings Announcement Date: CryoPort (CYRX) is set to announce its Q1 earnings on May 4th after market close, with a consensus EPS estimate of -$0.19, reflecting a 32.1% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: Analysts project Q1 revenue of $44.86 million, representing a 9.3% year-over-year increase, suggesting that the company is making strides in the commercialization of cell therapies, which could lay the groundwork for future growth.
- Performance Against Estimates: Over the past year, CryoPort has only beaten EPS and revenue estimates 25% of the time, highlighting challenges in managing market expectations and potentially affecting investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates saw no upward revisions and three downward adjustments, while revenue estimates experienced five upward revisions and two downward adjustments, indicating market divergence and uncertainty regarding CryoPort's future performance.
See More
Cryoport to Announce Q1 2026 Financial Results on May 4
- Earnings Release Schedule: Cryoport will report its Q1 2026 financial results on May 4, 2026, after U.S. market close, providing a comprehensive review of the company's financial and operational performance to keep investors informed.
- Conference Call Details: On the same day at 5:00 PM ET, Cryoport's management will host a Q&A conference call to address investor inquiries regarding the reported results, with a slide deck to enhance communication effectiveness.
- Replay Availability: A recording of the Q&A session will be available approximately three hours after the live event on the company's website, and a dial-in replay will be accessible until May 11, 2026, ensuring that investors who missed the live call can still obtain the information.
- Global Business Overview: Cryoport focuses on integrated temperature-controlled supply chain solutions for life sciences, supporting biopharmaceutical companies and research institutions, and aims to enhance business reliability and agility through innovation and regulatory compliance.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
- Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
- Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
- Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
- Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
See More
Cryoport Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Cryoport reported Q1 revenue of $47.8 million, a 16% year-over-year increase, with commercial cell and gene therapy revenue rising 26% to $9.1 million, underscoring the company's market leadership and robust demand.
- Innovative Clinical Trial Support: As of March 31, Cryoport supported a record 766 global clinical trials, including 91 in Phase III, reflecting the company's strong influence in the biopharmaceutical sector and the ongoing growth in market demand.
- Optimistic Outlook: The company raised its full-year 2026 revenue guidance to $192 million to $196 million, expecting to achieve positive adjusted EBITDA in the second half of the year, indicating management's confidence in future performance and market potential.
- Product and Service Expansion: Cryoport introduced its new Fusion 800 series and successfully shipped its first cryopreserved clinical trial materials from its Houston and Belgium facilities to clients, marking significant progress in product delivery and market expansion.
See More
CRYOPORT Q1 REVENUE REACHES USD 47.8 MILLION, EXCEEDING IBES ESTIMATE OF USD 44.9 MILLION
- Revenue Comparison: Cryoport reported a revenue of USD 47.8 million for Q1, exceeding the estimated revenue of USD 44.9 million by Ibes.
- Financial Performance: The significant difference between actual revenue and estimates indicates a strong performance by Cryoport in the first quarter.
See More
CryoPort to Announce Q1 Earnings on May 4th
- Earnings Announcement Date: CryoPort (CYRX) is set to announce its Q1 earnings on May 4th after market close, with a consensus EPS estimate of -$0.19, reflecting a 32.1% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Growth Expectations: Analysts project Q1 revenue of $44.86 million, representing a 9.3% year-over-year increase, suggesting that the company is making strides in the commercialization of cell therapies, which could lay the groundwork for future growth.
- Performance Against Estimates: Over the past year, CryoPort has only beaten EPS and revenue estimates 25% of the time, highlighting challenges in managing market expectations and potentially affecting investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates saw no upward revisions and three downward adjustments, while revenue estimates experienced five upward revisions and two downward adjustments, indicating market divergence and uncertainty regarding CryoPort's future performance.
See More
Cryoport to Announce Q1 2026 Financial Results on May 4
- Earnings Release Schedule: Cryoport will report its Q1 2026 financial results on May 4, 2026, after U.S. market close, providing a comprehensive review of the company's financial and operational performance to keep investors informed.
- Conference Call Details: On the same day at 5:00 PM ET, Cryoport's management will host a Q&A conference call to address investor inquiries regarding the reported results, with a slide deck to enhance communication effectiveness.
- Replay Availability: A recording of the Q&A session will be available approximately three hours after the live event on the company's website, and a dial-in replay will be accessible until May 11, 2026, ensuring that investors who missed the live call can still obtain the information.
- Global Business Overview: Cryoport focuses on integrated temperature-controlled supply chain solutions for life sciences, supporting biopharmaceutical companies and research institutions, and aims to enhance business reliability and agility through innovation and regulatory compliance.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives that could influence investor decisions and market trends.
- Investor Focus: Analysts' opinions are particularly crucial when considering the purchase of SMTC stock, as these insights may affect investor confidence and willingness to buy, directly impacting stock prices.
- Source of Updates: A complete view of all analyst rating changes, including upgrades and downgrades, can be found on our analyst ratings page, providing a comprehensive perspective to help investors make informed decisions.
- Market Dynamics Impact: The adjustments in analysts' ratings not only reflect views on company fundamentals but may also influence overall market sentiment, subsequently affecting trading volumes and price fluctuations of related stocks.
See More
Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
- Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
- Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
- Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
- Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
See More
